High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

BACKGROUND: B-cell maturation antigen (BCMA) chimeric antigen receptor T (CAR-T) cell therapy has obtained promising results in relapsed or refractory multiple myeloma (R/R MM), while some patients do not response, or relapse in short term after treatment. Combining with anti-CD38 might solve the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yuanyan, Yin, Haisen, Zhao, Xinying, Jin, Dan, Liang, Yan, Xiong, Tao, Li, Lu, Tang, Wen, Zhang, Jiangzhao, Liu, Min, Yu, Zhuojun, Liu, Huimin, Zang, Sibin, Huang, Zhiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722124/
https://www.ncbi.nlm.nih.gov/pubmed/34980210
http://dx.doi.org/10.1186/s13046-021-02214-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722124/
https://www.ncbi.nlm.nih.gov/pubmed/34980210
http://dx.doi.org/10.1186/s13046-021-02214-z

Ejemplares similares